HSV vector-delivery of GDNF in a rat model of PD: Partial efficacy obscured by vector toxicity

Brain Research

Volumn 1024, Issue 1-2, 2004, Pages 1-15

  Monville, Christelle ^a   Torres, Eduardo ^a   Thomas, Eleri ^a   Scarpini, Cinzia G ^b   Muhith, Justna ^a   Lewis, Jeff ^a   Finn, Jaquie ^c   Smith, Chris ^b   Cai, Shijie ^b   Efstathiou, Stacey ^b   Howard, Keith ^d   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UK   (United Kingdom)

^d Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

6 Hydroxydopamine; Gene therapy; Glial cell line derived neurotrophic factor; Herpes simplex virus; Neuroprotection; Parkinson's disease

Indexed keywords

AMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE THERAPY; GENOME; HERPES SIMPLEX VIRUS; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; TRANSGENE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTORS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS;

EID: 4644350860     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.06.082     Document Type: Article

References (51)

1. D.N. Abrous, and S.B. Dunnett Paw reaching in rats: the staircase test Neurosci. Prot. 1994 1 11
2. R. Barker, and S.B. Dunnett Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat Exp. Brain Res. 101 1994 365 374
3. A. Bjorklund, C. Rosenblad, C. Winkler, and D. Kirik Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease Neurobiol. Dis. 4 1997 186 200
4. A. Bjorklund, D. Kirik, C. Rosenblad, B. Georgievska, C. Lundberg, and R.J. Mandel Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model Brain Res. 886 2000 82 98
5. T.M. Block, S. Deshmane, J. Masonis, J. Maggioncalda, T. Valyi-Nagi, and N.W. Fraser An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers Virology 192 1993 618 630
6. M.E. Boursnell, C. Entwisle, D. Blakeley, C. Roberts, I.A. Duncan, S.E. Chisholm, G.M. Martin, R. Jennings, C.D. Ni, I. Sobek, S.C. Inglis, and C.S. McLean A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease J. Infect. Dis. 175 1997 16 25
7. D.J. Brooks The early diagnosis of Parkinson's disease Ann. Neurol. 44 1998 S10 S18
8. P. Brundin, J. Karlsson, M. Emgard, G.S. Schierle, O. Hansson, A. Petersen, and R.F. Castilho Improving the survival of grafted dopaminergic neurons: a review over current approaches Cell Transplant 9 2000 179 195
9. D.E. Carpenter, and J.G. Stevens Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome Hum. Gene Ther. 7 1996 1447 1454
10. B.S. Drolet, G.C. Perng, R.J. Villosis, S.M. Slanina, A.B. Nesburn, and S.L. Wechsler Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant Virology 253 1999 96 106
11. S.B. Dunnett, and A. Bjorklund Prospects for new restorative and neuroprotective treatments in Parkinson's disease Nature 399 1999 A32 A39
12. M.J. During, J.R. Naegele, K.L. O'Malley, and A.I. Geller Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase Science 266 1994 1399 1403
13. S. Efstathiou, S. Kemp, G. Darby, and A.C. Minson The role of herpes simplex virus type 1 thymidine kinase in pathogenesis J. Gen. Virol. 70 Pt. 4 1989 869 879
14. J.M. Fearnley, and A.J. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 Pt. 5 1991 2283 2301
15. A. Forrester, H. Farrell, G. Wilkinson, J. Kaye, N. Davis-Poynter, and T. Minson Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted J. Virol. 66 1992 341 348
16. D.M. Gash, Z. Zhang, A. Ovadia, W.A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P.A. Lapchak, F. Collins, B.J. Hoffer, and G.A. Gerhardt Functional recovery in parkinsonian monkeys treated with GDNF Nature 380 1996 252 255
17. D.M. Gash, G.A. Gerhardt, and B.J. Hoffer Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates Adv. Pharmacol. 42 1998 911 915
18. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 2003
19. J.C. Glorioso, W.F. Goins, N. DeLuca, and D.J. Fink Development of herpes simplex virus as a gene transfer vector for the nervous system Gene Ther. 1 Suppl. 1 1994 S39
20. D.Y. Ho, and E.S. Mocarski Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse Proc. Natl. Acad. Sci. U. S. A. 86 1989 7596 7600
21. R.T. Javier, J.G. Stevens, V.B. Dissette, and E.K. Wagner A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state Virology 166 1988 254 257
22. D. Kirik, C. Rosenblad, and A. Bjorklund Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152 1998 259 277
23. D. Kirik, C. Rosenblad, A. Bjorklund, and R.J. Mandel Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system J. Neurosci. 20 2000 4686 4700
24. D. Kirik, B. Georgievska, C. Burger, C. Winkler, N. Muzyczka, R.J. Mandel, and A. Bjorklund Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer Proc. Natl. Acad. Sci. U. S. A. 99 2002 4708 4713
25. D.M. Krisky, D. Wolfe, W.F. Goins, P.C. Marconi, R. Ramakrishnan, M. Mata, R.J. Rouse, D.J. Fink, and J.C. Glorioso Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons Gene Ther. 5 1998 1593 1603
26. R.H. Lachmann, and S. Efstathiou Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system J. Virol. 71 1997 3197 3207
27. S. Laquerre, W.F. Goins, S. Motiuchi, T. Oligino, D.M. Krisky, J.C. Marconi, M.K. Soares, J. Cohen, J. Glorioso, and D.J. Fink Gene-transfer tool: herpes simplex virus vectors T. Friedman The Development of Human Gene Therapy 1999 Cold Spring Harbor Laboratory Press New York 173 208
28. D.S. Latchman, and R.S. Coffin Viral vectors for gene therapy in Parkinson's disease Rev. Neurosci. 12 2001 69 78
29. J.M. Loutsch, G.C. Perng, J.M. Hill, X. Zheng, M.E. Marquart, T.M. Block, H. Ghiasi, A.B. Nesburn, and S.L. Wechsler Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes J. Virol. 73 1999 767 771
30. P.R. Lowenstein, E.E. Morrison, D. Bain, P. Hodge, C.M. Preston, P. Clissold, N.D. Stow, T.A. McKee, and M.G. Castro Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro Neuroscience 60 1994 1059 1077
31. K.R. Marshall, R.H. Lachmann, S. Efstathiou, A. Rinaldi, and C.M. Preston Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression J. Virol. 74 2000 956 964
32. C.P. Montoya, L.J. Campbell-Hope, K.D. Pemberton, and S.B. Dunnett The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats J. Neurosci. Methods 36 1991 219 228
33. A. Natsume, M. Mata, J. Goss, S. Huang, D. Wolfe, T. Oligino, J. Glorioso, and D.J. Fink Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration Exp. Neurol. 169 2001 231 238
34. G. Nikkhah, M.G. Cunningham, A. Jodicke, U. Knappe, and A. Bjorklund Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model Brain Res. 633 1994 133 143
35. J.A. Olschowka, W.J. Bowers, S.D. Hurley, M.A. Mastrangelo, and H.J. Federoff Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS Molec. Ther. 7 2003 218 227
36. S. Palfi, L. Leventhal, Y. Chu, S.Y. Ma, M. Emborg, R. Bakay, N. Deglon, P. Hantraye, P. Aebischer, and J.H. Kordower Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration J. Neurosci. 22 2002 4942 4954
37. S. Palfi, L. Leventhal, Y. Chu, S.Y. Ma, M. Emborg, R. Bakay, N. Deglon, P. Hantraye, P. Aebischer, and J.H. Kordower Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration J. Neurosci. 22 2002 4942 4954
38. G.C. Perng, J.C. Zwaagstra, H. Ghiasi, R. Kaiwar, D.J. Brown, A.B. Nesburn, and S.L. Wechsler Similarities in regulation of the HSV-1 LAT promoter in corneal and neuronal cells Invest. Ophthalmol. Vis. Sci. 35 1994 2981 2989
39. G.C. Perng, H. Ghiasi, S.M. Slanina, A.B. Nesburn, and S.L. Wechsler The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript J. Virol. 70 1996 976 984
40. G.C. Perng, S.M. Slanina, H. Ghiasi, A.B. Nesburn, and S.L. Wechsler A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1 J. Virol. 70 1996 2014 2018
41. G.C. Perng, S.M. Slanina, A. Yukht, B.S. Drolet, W. Keleher Jr., H. Ghiasi, A.B. Nesburn, and S.L. Wechsler A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation J. Virol. 73 1999 920 929
42. G.C. Perng, C. Jones, J. Ciacci-Zanella, M. Stone, G. Henderson, A. Yukht, S.M. Slanina, F.M. Hofman, H. Ghiasi, A.B. Nesburn, and S.L. Wechsler Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript Science 287 2000 1500 1503
43. G.C. Perng, S.M. Slanina, A. Yukht, H. Ghiasi, A.B. Nesburn, and S.L. Wechsler The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits J. Virol. 74 2000 1885 1891
44. L.A. Samaniego, L. Neiderhiser, and N.A. DeLuca Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins J. Virol. 72 1998 3307 3320
45. C.G. Scarpini, J. May, R.H. Lachmann, C.M. Preston, S.B. Dunnett, E.M. Torres, and S. Efstathiou Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors Gene Ther. 8 2001 1057 1071
46. F. Sedarati, K.M. Izumi, E.K. Wagner, and J.G. Stevens Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons J. Virol. 63 1989 4455 4458
47. I. Steiner, J.G. Spivack, R.P. Lirette, S.M. Brown, A.R. MacLean, J.H. Subak-Sharpe, and N.W. Fraser Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection EMBO J. 8 1989 505 511
48. M. Sun, G.R. Zhang, L. Kong, C. Holmes, X. Wang, W. Zhang, D.S. Goldstein, and A.I. Geller Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino Acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector Hum. Gene Ther. 14 2003 415 424
49. R.L. Thompson, and N.M. Sawtell The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency J. Virol. 71 1997 5432 5440
50. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy- dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
51. L. Wang, S. Muramatsu, Y. Lu, K. Ikeguchi, K. Fujimoto, T. Okada, H. Mizukami, Y. Hanazono, A. Kume, F. Urano, H. Ichinose, T. Nagatsu, I. Nakano, and K. Ozawa Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease Gene Ther. 9 2002 381 389